The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.

J Transl Med · 2023 · PMC10601323 · PMID 37880788

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

We observed four patients who developed ICI-DM following immunotherapy with nivolumab + relatlimab; this frequency was higher than reported in the literature, but this may not be significant, due to the reduced numerosity of this group, representing a limitation of our study [ 22 ].

also in 1,145 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.